All proteomic data used in our study were taken from The Cancer Proteome Atlas web site (<http://www.tcpaportal.org/tcpa/> Reference: Li J, et al. Nat. Methods. 2013, TCPA: a resource for cancer functional proteomics data, doi:[10.1038/nmeth.2650](https://doi.org/10.1038/nmeth.2650)). All data are available without restrictions on their use in publications or presentations as declared in the web site: <https://cancergenome.nih.gov/publications/publicationguidelines> \[last visited: 13 Oct 2017\].

Introduction {#sec001}
============

In bioinformatics, various approaches are leveraged to understand the molecular perturbations observed on cells or tissues caused by a disease, such as cancer, autism, diabetes, Alzheimer\'s. One of these approaches is inferring the gene networks, which can illustrate the gene-gene and protein-protein interactions from an expression dataset to understand the cell physiology and disease pathogenesis and to estimate the genome-wide working mechanism of proteins and genes \[[@pone.0188016.ref001],[@pone.0188016.ref002]\]. In this study, effects of the association estimators on the network inference methods, which are frequently utilized in bioinformatics studies to detect molecular structures related to a given disease, were evaluated via the proteomic data of five different cancer types generated by TCPA \[[@pone.0188016.ref003]\]. The five cancer types used in this study are among the most common types according to the recently published results by the American Cancer Society \[[@pone.0188016.ref004]\].

In previous studies, both the synthetic and real gene expression data sets obtained from the microarray assays are mainly used to analyze the association estimators' effect on the gene network inference techniques. Olsen et al. \[[@pone.0188016.ref005]\] evaluated the performance of Pearson, Spearman, Empirical, Miller-Madow (MM), and Shrink association estimators on three network inference algorithms (Algorithm for the Reconstruction of Accurate Cellular Networks--ARACNE \[[@pone.0188016.ref006]\], Context-Likelihood of Relatedness--CLR \[[@pone.0188016.ref007]\], Network inference with maximum relevance/minimum redundancy feature selection--MRNET \[[@pone.0188016.ref008]\]) by using synthetic and real microarray data sets. In addition, the Empirical, MM and Shrink estimators were used to examine the equal width (EW) and equal frequency (EF) discretization methods' effects on the performance of the association estimators \[[@pone.0188016.ref005]\]. As a result, MRNET with the Spearman and CLR with the Pearson yielded more successful results on the synthetic dataset, and also significant results were obtained on the real dataset, as well \[[@pone.0188016.ref005]\]. Simoes and Streib \[[@pone.0188016.ref009]\] used the MM, ML, Shrink and SG association estimators with three different discretization methods (EW, EF, global equal width---GEW) together with The Conservative Causal Core NETwork (C3NET) \[[@pone.0188016.ref010]\] network inference algorithm by using the synthetic gene microarray data sets to examine the effects of both the estimators and the discretization methods on the network inference algorithms. They found that the MM estimator outperformed the other estimators when used with the EW discretization method. Daub et al. \[[@pone.0188016.ref011]\], investigated the performances of the B-spline (BS) and Kernel Density Estimator (KDE) methods on large-scale gene expression data sets. As a result, they found that the performance of the BS estimator varied for different spline values. The order of success is as follows BS (spline order = 3) \> KDE \> BS (spline order = 1). Kurt et al. \[[@pone.0188016.ref012]\], used two synthetic and two biological data sets to evaluate 14 association estimators with 3 different network inference algorithms. Also they observed that the influences of the Copula Transform (CT) pre-processing operation on the performance of the association estimators. B-spline, Pearson-based Gaussian and Spearman-based Gaussian estimators are observed as the best performing ones among all. Also CT operation increased inference performances of the estimators for synthetic datasets.

Network inference methods have been used in multiple studies on different cancer types. Şenbabaoğlu et al. \[[@pone.0188016.ref013]\] analyzed the protein expression data, which was obtained from TCPA, from 3467 patients with 11 different types of cancer by using 13 different network inference methods. The most successful network inference method was varying based on the cancer type. Madhamshettiwar et al. \[[@pone.0188016.ref014]\] searched the biological mechanisms related to the ovarian cancer using 7 different network inference methods.

WGCNA \[[@pone.0188016.ref015]\] is one of the most commonly used gene network inference and clustering approaches and is used to find highly correlated gene/protein modules (cluster, sub-network) related to a given disease and hub genes/proteins with high connectivity in these modules. WGCNA has been used to analyze gene/protein expression data from brain cancer \[[@pone.0188016.ref016]\], yeast cell cycle \[[@pone.0188016.ref017]\], mouse genetics \[[@pone.0188016.ref018],[@pone.0188016.ref019]\], diabetes \[[@pone.0188016.ref020]\] and many other diseases and complex traits.

It has been reported that the correlation-based methods are not sufficient to estimate the non-linear relationships between the cell molecules such as the complex molecular interactions related to a cancer type \[[@pone.0188016.ref021]\]. Many algorithms have been developed to solve this problem by using mutual information based methods \[[@pone.0188016.ref006]--[@pone.0188016.ref008],[@pone.0188016.ref010]\].

We proposed a system integrating the MI-based association estimators with the co-expression network clustering technique to identify the sub networks associated with the diseases. Leveraging the MI-based estimators in WGCNA instead of the correlation-based ones, which are the default and only options presented in the WGCNA, can capture both linear and non-linear interactions between the protein-protein pairs and improves the estimation of disease-associated molecular mechanisms and interactions, while the correlation-based ones can only capture the disease mechanisms based on the linear interactions. To estimate the disease associated sub networks and mechanisms, we leveraged the MI-based estimators within the *co-expression network methodology* different than the previous studies \[[@pone.0188016.ref013],[@pone.0188016.ref014]\] that were interested in global networks and not focusing on the individual sub networks or co-expression modules. Also different discretization methods were used to estimate the association estimators that are widely used in gene network inference, and an evaluation framework was developed to analyze the as-obtained results unlike \[[@pone.0188016.ref013],[@pone.0188016.ref014]\]. Besides, we identified the hub genes of the sub networks to reveal the potential key regulators of these sub networks, which were not searched in \[[@pone.0188016.ref006]--[@pone.0188016.ref008]\]. We observed that according to whole cancer datasets used in our study Shrink, SG, BS, MM and Shrink methods identified the most disease-relevant sub networks and genes with average precision scores of 0.85, 0.84, 0.59, 0.76 and 0.76 (for BRCA, GBM, LUSC, KIRC, and SKCM datasets), respectively. Moreover, unlike previous studies \[[@pone.0188016.ref005]\], \[[@pone.0188016.ref009]\], \[[@pone.0188016.ref011],[@pone.0188016.ref012]\], in our study, five real cancer proteomic data sets that are obtained from TCPA were examined by biological network inference method along with nine different association estimators to compare the association estimators' performance.

Materials and methods {#sec002}
=====================

Materials {#sec003}
---------

Studies in bioinformatics field have gained a great momentum along with the developments in high-throughput techniques. One of these techniques is the reverse phase protein array (RPPA) \[[@pone.0188016.ref022]\] technology, which is a high-throughput antibody-based technique and it supplies protein expression data for proteomics research. Sheehan et al. \[[@pone.0188016.ref023]\] performed an analysis on ovarian cancer data obtained by RPPA. TCPA has obtained protein expression data from numerous cell line and tumor samples using RPPA technique. The detailed information about the process of preparing the data set before the analysis is given in \[[@pone.0188016.ref003]\].

The RPPA data used in this study was downloaded from **Download** section (level 4) in TCPA's web site \[[@pone.0188016.ref024]\]. It is comprised of proteomic expression data of 2230 cancer patients in 5 cancer types. There are more than 218 antibodies for each patient. To obtain the individual gene-protein matching ([S1 Table](#pone.0188016.s004){ref-type="supplementary-material"}) of the data, a process was performed after taking the relevant information from **My Protein** section of TCPA's \[[@pone.0188016.ref024]\] web site. The file containing the expression data of the selected antibodies (proteins) for each cancer type is given ([S2](#pone.0188016.s005){ref-type="supplementary-material"}--[S6](#pone.0188016.s009){ref-type="supplementary-material"} Tables). The type of the cancers, their sample sizes, number of proteins (antibodies), number of selected antibodies and their abbreviations are listed in [Table 1](#pone.0188016.t001){ref-type="table"}.

10.1371/journal.pone.0188016.t001

###### The type of cancers and their sample sizes (Level 4).

![](pone.0188016.t001){#pone.0188016.t001g}

      The cancer tumor type          Cancer abbreviation   Number of samples   Number of proteins   Number of selected proteins
  --- ------------------------------ --------------------- ------------------- -------------------- -----------------------------
  1   Breast invasive carcinoma      BRCA                  901                 224                  173
  2   Glioblastoma multiforme        GBM                   205                 223                  173
  3   Lung squamous cell carcinoma   LUSC                  325                 237                  170
  4   Clear cell kidney carcinoma    KIRC                  445                 233                  169
  5   Skin Cutaneous Melanoma        SKCM                  354                 223                  173

Furthermore, to evaluate the performances of the association estimators, DisGeNET and MSigDB were used as gold standards. DisGeNET curates the gene-disease and genetic variant-disease associations that were reported in previous studies and stored in multiple publically available data sources such as UNIPROT database, the Comparative Toxicogenomics Database, GWAS catalog, and also it contains 429,036 associations between 17,381 genes and 15,093 diseases \[[@pone.0188016.ref025],[@pone.0188016.ref026]\]. In MSigDB, there are 17,779 gene sets in total, from 8 different collections, namely hallmark gene sets, positional gene sets, curated gene sets, motif gene sets, computational gene sets, Gene Ontology (GO) gene sets, oncogenic gene sets, and immunologic gene sets \[[@pone.0188016.ref027]\].

Based on each cancer type, the search terms used to obtain the data, the Unified Medical Language System---Concept Unique Identifiers (UMLS-CUIs), number of the genes obtained from DisGeNET with a number of supporting publications (PMIDs) ≥ 2 and the overlapped number of the genes between the selected cancer dataset and DisGeNET are given in [Table 2](#pone.0188016.t002){ref-type="table"}. The gene level analysis was performed by using the relevant cancer-related DisGeNET data.

10.1371/journal.pone.0188016.t002

###### Information of data from DisGeNET.

![](pone.0188016.t002){#pone.0188016.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------
      Cancer\   Search terms on DisGeNET          UMLS-CUIs   DisGeNET gene number\   Overlapped Gene number between TCPA Dataset and DisGeNET
      Type                                                    (PMIDs\> = 2)           
  --- --------- --------------------------------- ----------- ----------------------- ----------------------------------------------------------
  1   BRCA      Breast Cancer                     C0346153    52                      15

  2   GBM       Glioblastoma Multiforme           C1621958    147                     28

  3   LUSC      Squamous cell carcinoma of lung   C0149782    41                      7

  4   KIRC      Kidney Diseases                   C0022658    264                     14

  5   SKCM      Cutaneous Melanoma                C0151779    104                     25
  ----------------------------------------------------------------------------------------------------------------------------------------------

UMLS-CUIs is abbreviation of Unified Medical Language System---Concept Unique Identifiers and PMIDs is the number of supporting publications.

By using the selected disease genes from DisGeNET for each cancer type, the top associated 100 biological pathways were identified from the BioCarta, KEGG, and Reactome databases with a false discovery rate (FDR)\<0.05 by using MSigDB online tool. FDR score is the adjusted version of the raw p-value for the multiple hypothesis testing. Here, Bonferroni correction was used to correct the raw p-values \[[@pone.0188016.ref028]\], in which the p-values are multiplied by the number of hypotheses that were tested. The pathway level analysis was performed by using the top relevant biological pathways of the disease genes obtained from the DisGeNET.

Methods {#sec004}
-------

In this study, the association scores between the proteins were calculated by using Spearman \[[@pone.0188016.ref005]\], Pearson \[[@pone.0188016.ref005]\], Kendall Tau (Kendall) \[[@pone.0188016.ref029]\] correlation methods. BS \[[@pone.0188016.ref011]\], Empirical \[[@pone.0188016.ref030]\], KDE \[[@pone.0188016.ref031]\], MM \[[@pone.0188016.ref032]\], Shrink \[[@pone.0188016.ref033]\], and SG \[[@pone.0188016.ref034]\] MI-based association estimators were also used in our analyses. Moreover, the influence of the discretization methods (EW, EF, GEW) on the Empirical, MM, Shrink, and SG estimators' inference performances was also examined. Details of the association estimator and the discretization methods used in this study can be found in \[[@pone.0188016.ref005],[@pone.0188016.ref012],[@pone.0188016.ref033],[@pone.0188016.ref035]\]. All these methods were used as an alternative to the correlation-based *adjacency* function of WGCNA package that is used to calculate the Pearson and Spearman correlation scores between the protein pairs. We compared the MI-based and correlation-based methods within the co-expression network concept and evaluated their disease relevance in both pathway and gene-level.

The WGCNA steps were performed as follows;

-   Firstly, the association matrix (*adjacency*) of the proteins in the data set is calculated using the protein expression data.

-   A network-related similarity matrix is obtained by using a topological overlap measure (TOM) \[[@pone.0188016.ref036]\], which has been successfully applied in different studies \[[@pone.0188016.ref037]\] in the literature, to identify the heavily interrelated protein clusters (*TOMsimilarity* measure).

-   The obtained similarity matrix is subtracted from one (1-TOM) to identify a dissimilarity measure. From the dissimilarity matrix, a clustering tree is formed to identify the cluster of related proteins via hierarchical clustering (*hclust*).

-   To find highly correlated gene/protein co-expression modules in the generated clustering tree of the gene networks, we used the dynamic branch cut methods \[[@pone.0188016.ref038]\] (*cutreeDynamic*) with different parameters (see [S7 Table](#pone.0188016.s010){ref-type="supplementary-material"}). Finally, gene/protein with the highest connectivity in each module (hub gene) is determined. (*chooseOneHubInEachModule*).

In this study, we used one-tailed version of the Fisher\'s exact test (FET) \[[@pone.0188016.ref039]\], which is identical to the hypergeometric test to calculate the P-values representing the association of the co-expression modules with the given cancer type. A hypergeometric test is adopted from \[[@pone.0188016.ref040]\], whose distribution (used to calculate P-value) is given in (1) where n and k as integer, $(_{k}^{n})$ is the binomial coefficient, I is the number of inferred genes/proteins of network inference method, V is the number of genes/proteins in the DisGeNET database to use for verification, O is the number of overlap between I and V. AGP (all genes/proteins) is the number of all known genes/proteins for human genome.

![](pone.0188016.e002.jpg){#pone.0188016.e002g}
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If the calculated P-value is less than 0.05, the overlapped proteins between the inferred modules and disease-related DisGeNET genes and their relevant pathways, are considered less likely to be random and these modules are more likely to be disease-associated and biologically interesting. [Fig 1](#pone.0188016.g001){ref-type="fig"} and [Table 3](#pone.0188016.t003){ref-type="table"} are illustrated to provide a better understanding for the use of FET for the overall assessment of the association estimators' performances. As given in [Fig 1](#pone.0188016.g001){ref-type="fig"}, based on the given two clusters (e.g., inferred and validated genes/proteins), it was determined whether the overlap is statistically significant according to all genes/proteins (AGP) in the literature. Recent studies have revealed that the number of genes in the human genome is around 19,000 \[[@pone.0188016.ref041]\] and we used this value as AGP in our study. [Table 3](#pone.0188016.t003){ref-type="table"} summarizes the regions shown in [Fig 1](#pone.0188016.g001){ref-type="fig"} and is used as an input in the FET.

![Overlap analysis with FET.\
Here, *I* is the count of inferred genes/proteins of network inference method (e.g., WGCNA). *V* is the count of genes/proteins in the literature database (e.g., DisGeNET, MSigDB) to search for verification. O is the number of overlap between *I* and *V*. *AGP* is the count of all genes/proteins in the literature.](pone.0188016.g001){#pone.0188016.g001}

10.1371/journal.pone.0188016.t003

###### FET parameters in gene level.

![](pone.0188016.t003){#pone.0188016.t003g}

  -----------------------------------------------------------------------------------------
                                      Inferred Genes/Proteins\   Inferred Genes/Proteins\
                                      (in the literature)        (not in the literature)
  ----------------------------------- -------------------------- --------------------------
  **Genes/Proteins (Inferred)**       *O*                        *I--O*

  **Genes/Proteins (Not inferred)**   *V---O*                    *AGP--I--V + O*
  -----------------------------------------------------------------------------------------

*I* is the count of inferred genes/proteins of network inference method. *V* is the count of genes/proteins in the literature database to search for verification. *O* is the number of overlap between *I* and *V*. AGP is the count of all genes/proteins in the literature.

Ultimate assessment metric used in the evaluation process is the *precision* score: $$p = \frac{TP}{TP + FP}$$ where *p* is precision, *TP* is number of the true positives, *FP* is number of the false positives. TPs denote the modules which satisfying the required conditions in the pathway-level or gene-level analysis (P-value\<0.05). FPs denote the number of modules which are not satisfying the required conditions in the pathway-level or gene-level analyses. The required conditions are described in Proposed Framework section.

### Association estimators used in the reconstruction process of the co-expression networks {#sec005}

For the analyses, the *build*.*mim* function from the **minet** \[[@pone.0188016.ref035]\], the *obtain*.*mim* function from the **DepEst** \[[@pone.0188016.ref042]\] and the *chooseOneHubInEachModule*, *adjacency*, *TOMsimilarity*, *cutreeDynamic* and *hclust* functions from the **WGCNA** packages were used. The selected association estimators are indicated by the specific parameter values provided to the *build*.*mim* and *obtain*.*mim* functions.

### Proposed framework {#sec006}

In this section, the proposed framework to analyze the performances of the association estimators is illustrated in [Fig 2](#pone.0188016.g002){ref-type="fig"}.

![Proposed framework.](pone.0188016.g002){#pone.0188016.g002}

1.  In the first step the proteomic data is downloaded from TCPA and prepared for the analysis (see *Materials* section).

2.  In the second step, co-expression networks and modules were created using WGCNA as described in *Methods* section. The interaction score matrix to be used in the subsequent steps was calculated by using the adjacency function and other association estimators provided by DepEst \[[@pone.0188016.ref042]\] and minet \[[@pone.0188016.ref035]\] packages. In addition, parameters that generate at least 7 modules (sub-networks) for each association estimator were found by using certain parameters (see [S7 Table](#pone.0188016.s010){ref-type="supplementary-material"}). 7, 8, and 9 modules are generated from the co-expression networks for each association estimator from each dataset. The reason why the module numbers are selected as 7-8-9 is shown in ([S1](#pone.0188016.s001){ref-type="supplementary-material"} and [S2](#pone.0188016.s002){ref-type="supplementary-material"} Figs) and details are explained in [S1 Text](#pone.0188016.s013){ref-type="supplementary-material"}. The modules created with the parameters listed in [S8 Table](#pone.0188016.s011){ref-type="supplementary-material"} were used in the comparison of the association estimators.

3.  In the 3rd step, the genes that were confirmed to be related with the given cancer type in at least two different studies (PMIDs ≥ 2) were obtained for each cancer type by using DisGeNET web page \[[@pone.0188016.ref043]\].

4.  In this step, by using the MSigDB web page \[[@pone.0188016.ref044]\], we identified the top 100 biological pathways from the BioCarta, KEGG and Reactome databases, that are significantly associated with the disease-related gene list with a FDR q-value \<0.05.

5.  Pathway-level analysis by FET: In this step, overlapping ratios and corresponding *P*-values of the association between the pathways obtained at the 4th step and the modules identified in step 2 were found by using FET. To correct the raw P-values for the multiple hypothesis testing, the FDR q-value was calculated by multiplying the P-value by 100 since we selected the top 100 pathways associated with the DisGeNET genes in the previous step. To evaluate our findings in the pathway level, WGCNA modules containing at least 5 shared genes with at least two of the disease-associated pathways found in Step 4 with an FDR q-value \<0.05 were considered as a successful hit (*TP*) in terms of disease relevance. The reason why at least 2 pathways and 5 genes are selected as cut-off is shown in [S3 Fig](#pone.0188016.s003){ref-type="supplementary-material"} and details are explained in [S2 Text](#pone.0188016.s014){ref-type="supplementary-material"}. Number of the modules satisfying these conditions are divided by the total number of the modules *(TP+FP)* to obtain the *pathway level* performance scores (*precision*) of the association estimators. The precision ratios at the pathway level are given in [Table 4](#pone.0188016.t004){ref-type="table"} and [Fig 3](#pone.0188016.g003){ref-type="fig"} by module numbers for each association estimator.

6.  Gene-level analysis by FET: To evaluate our findings in gene level, the overlapping ratios between the genes in modules passing the overlap analysis test at the pathway level overlap analysis and the genes obtained from DisGeNET were calculated via FET, and the resulting modules which have p-values lower than 0.05 were considered as significantly associated (*TP*) with the corresponding cancer type. By dividing the number of modules that satisfy these conditions by the total number of modules (*TP+FP*), we obtained the *gene level* performance scores (*precision*) of the association estimators estimator (see [S9 Table](#pone.0188016.s012){ref-type="supplementary-material"} for details of the gene-level analysis scores by FET). The precision scores at the gene level are given in [Table 5](#pone.0188016.t005){ref-type="table"} by module numbers for each association estimator, and the graphical representation of the hub genes of the significantly disease-relevant modules is given in [Fig 4](#pone.0188016.g004){ref-type="fig"}. In this step, the hub genes within the disease-associated sub-networks, which are identified by the most successful estimator of step 5, and the neighboring genes that are located at the center of these hub genes are illustrated in Figs [5](#pone.0188016.g005){ref-type="fig"}--[9](#pone.0188016.g009){ref-type="fig"} for BRCA, GBM, KIRC, LUSC, SKCM cancer type, respectively. The hub genes and the genes that have been experimentally confirmed to be associated with the disease and reported in DisGeNET within the hub gene neighborhood are illustrated with colored and larger nodes in Figs [5](#pone.0188016.g005){ref-type="fig"}--[9](#pone.0188016.g009){ref-type="fig"}. The genes that are not colored but have a red frame in Figs [5](#pone.0188016.g005){ref-type="fig"}--[9](#pone.0188016.g009){ref-type="fig"} have a PMID value of one. There is no entry in DisGeNET for the grey colored nodes. Also, the top three pathways, to which each module is related, are given above or below the relevant module to annotate each module.

![Pathway level analysis results by module number for each cancer type.\
Precision scores of A) BRCA, B) GBM, C) KIRC, D) LUSC, and E) SKCM datasets. The abbreviations: BS, B-spline; KDE, Kernel Density Estimator; MM, Miller-Madow; SG, Schurmann-Grassberger; Shrink, James-Stein Shrinkage. Avg is the average performance score of the association estimators according to the constructed module sizes.](pone.0188016.g003){#pone.0188016.g003}

![Gene level analysis results by module number for each cancer type (P-value ≤ 0.05).\
Precision scores of A) BRCA, B) GBM, C) KIRC, D) LUSC, and E) SKCM datasets. The abbreviations: BS, B-spline; KDE, Kernel Density Estimator; MM, Miller-Madow; SG, Schurmann-Grassberger; Shrink, James-Stein Shrinkage. Avg is the average performance score of the association estimators according to the constructed module sizes.](pone.0188016.g004){#pone.0188016.g004}

![The hub genes and neighbors in the disease-related sub-networks obtained by the most successful Shrink method (in terms of precision score) on BRCA dataset.\
*MSH6* and *GATA3* are validated in one study according to DisGeNET. *PDK1* and *SMAD4* genes (proteins) were also shown to be associated with the BRCA in multiple studies though they were not reported in the DisGeNET. The genes registered in DisGeNET and experimentally confirmed for the diseases, are shown with colored and larger nodes. Among those, genes that are not colored but have a red frame have a PMID value of one. There is no entry in DisGeNET for the grey colored nodes.](pone.0188016.g005){#pone.0188016.g005}

![The hub genes and neighbors in the disease-related sub-networks obtained by the most successful SG method (in terms of precision score) on GBM dataset.\
*IGF1R* is validated in one study according to DisGeNET. In recent study, *RAD50* gene (protein) was also shown to be associated with the GBM, though it was not reported in the DisGeNET. The genes registered in DisGeNET and experimentally confirmed for the diseases, are shown with colored and larger nodes. Among those, genes that are not colored but have a red frame have a PMID value of one. There is no entry in DisGeNET for the grey colored nodes.](pone.0188016.g006){#pone.0188016.g006}

![The hub genes and neighbors in the disease-related sub-networks obtained by the most successful Shrink method (in terms of precision score) on KIRC dataset.\
The genes registered in DisGeNET and experimentally confirmed for the diseases, are shown with colored and larger nodes. Among those, genes that are not colored but have a red frame have a PMID value of one. There is no entry in DisGeNET for the grey colored nodes.](pone.0188016.g007){#pone.0188016.g007}

![The hub genes and neighbors in the disease-related sub-networks obtained by the most successful BS method (in terms of precision score) on LUSC dataset.\
*EIF4G1* is validated in multiple studies according to DisGeNET. In recent studies, *FOXM1* and *CDKN1A (P21)* genes (proteins) were also shown to be associated with the LUSC, though they were not reported in the DisGeNET. The genes registered in DisGeNET and experimentally confirmed for the diseases, are shown with colored and larger nodes. Among those, genes that are not colored but have a red frame have a PMID value of one. There is no entry in DisGeNET for the grey colored nodes.](pone.0188016.g008){#pone.0188016.g008}

![The hub genes and neighbors in the disease-related sub-networks obtained by the most successful MM method (in terms of precision score) on SKCM dataset.\
In recent studies, *ETS1* gene (protein) was also shown to be associated with the SKCM, though it was not reported in the DisGeNET. The genes registered in DisGeNET and experimentally confirmed for the diseases, are shown with colored and larger nodes. Among those, genes that are not colored but have a red frame have a PMID value of one. There is no entry in DisGeNET for the grey colored nodes.](pone.0188016.g009){#pone.0188016.g009}

10.1371/journal.pone.0188016.t004

###### Pathway level precision ratios by module numbers for each cancer type.

![](pone.0188016.t004){#pone.0188016.t004g}

              BRCA   GBM    KIRC   LUSC       SKCM                                                                                                                 
  ----------- ------ ------ ------ ---------- ------ ------ ------ ---------- ------ ------ ------ ---------- ------ ------ ------ ---------- ------ ------ ------ -----------
  Adjacency   0.86   0.63   0.33   0.61       0.57   0.63   0.56   0.58       0.43   0.63   0.33   0.46       0.71   0.75   0.56   0.67       0.86   0.63   0.56   0.68
  Kendall     0.57   0.50   0.44   0.51       0.71   0.63   0.67   0.67       0.57   0.38   0.33   0.43       0.57   0.50   0.44   0.51       0.71   1.00   0.56   **0.757**
  Pearson     0.71   0.50   0.56   0.59       0.43   0.75   0.44   0.54       0.57   0.38   0.33   0.43       0.57   0.75   0.44   0.59       0.71   0.75   0.67   0.71
  Spearman    0.57   0.50   0.67   0.58       0.57   0.38   0.44   0.46       0.71   0.25   0.33   0.43       0.57   0.38   0.44   0.46       0.71   0.75   0.67   0.71
  BS          0.71   0.63   0.44   0.59       0.57   0.63   0.67   0.62       0.43   0.63   0.33   0.46       0.86   0.75   0.67   **0.76**   0.86   0.63   0.56   0.68
  Empirical   0.71   0.75   0.56   0.67       0.71   0.50   0.56   0.59       0.57   0.38   0.22   0.39       0.86   0.75   0.44   0.68       0.86   0.63   0.56   0.68
  KDE         0.43   0.50   0.33   0.42       0.86   0.63   0.44   0.64       0.43   0.25   0.33   0.34       0.71   0.63   0.56   0.63       0.86   0.63   0.56   0.68
  MM          0.86   0.38   0.33   0.52       0.86   0.75   0.56   0.72       0.71   0.38   0.33   0.47       0.71   0.75   0.56   0.67       0.86   0.75   0.67   **0.758**
  SG          0.71   0.63   0.56   0.63       0.86   0.88   0.78   **0.84**   0.57   0.50   0.22   0.43       0.86   0.63   0.44   0.64       0.71   0.63   0.67   0.67
  Shrink      1.00   0.88   0.67   **0.85**   0.71   0.63   0.56   0.63       0.71   0.63   0.44   **0.59**   0.71   0.88   0.67   **0.75**   1.00   0.63   0.56   0.73

10.1371/journal.pone.0188016.t005

###### Gene level precision ratios by module numbers for each cancer type (P-value \<0.05).

![](pone.0188016.t005){#pone.0188016.t005g}

              BRCA   GBM    KIRC   LUSC       SKCM                                                                                                                 
  ----------- ------ ------ ------ ---------- ------ ------ ------ ---------- ------ ------ ------ ---------- ------ ------ ------ ---------- ------ ------ ------ -----------
  Adjacency   0.86   0.63   0.33   0.61       0.57   0.63   0.56   0.58       0.29   0.50   0.33   0.37       0.57   0.75   0.56   0.63       0.86   0.63   0.56   0.68
  Kendall     0.57   0.50   0.44   0.51       0.71   0.63   0.67   0.67       0.43   0.25   0.33   0.34       0.57   0.38   0.33   0.43       0.71   1.00   0.56   **0.757**
  Pearson     0.71   0.50   0.56   0.59       0.43   0.75   0.44   0.54       0.43   0.38   0.33   0.38       0.57   0.63   0.44   0.55       0.71   0.75   0.67   0.71
  Spearman    0.43   0.38   0.56   0.45       0.57   0.38   0.44   0.46       0.57   0.25   0.11   0.31       0.57   0.25   0.33   0.38       0.57   0.63   0.67   0.62
  BS          0.57   0.50   0.44   0.51       0.57   0.63   0.67   0.62       0.43   0.63   0.33   0.46       0.57   0.75   0.67   **0.66**   0.86   0.63   0.56   0.68
  Empirical   0.71   0.75   0.56   0.67       0.71   0.50   0.56   0.59       0.57   0.38   0.11   0.35       0.71   0.63   0.44   0.59       0.86   0.63   0.56   0.68
  KDE         0.43   0.50   0.33   0.42       0.86   0.50   0.44   0.60       0.43   0.25   0.33   0.34       0.57   0.38   0.44   0.46       0.86   0.63   0.56   0.68
  MM          0.86   0.38   0.33   0.52       0.86   0.75   0.56   0.72       0.71   0.25   0.33   0.43       0.43   0.75   0.44   0.54       0.86   0.75   0.67   **0.758**
  SG          0.71   0.63   0.56   0.63       0.86   0.88   0.67   **0.80**   0.43   0.25   0.22   0.30       0.71   0.63   0.44   0.59       0.71   0.63   0.67   0.67
  Shrink      1.00   0.88   0.67   **0.85**   0.71   0.63   0.56   0.63       0.57   0.50   0.44   **0.51**   0.57   0.63   0.67   0.62       1.00   0.63   0.56   0.73

Results {#sec007}
=======

As shown in [Table 4](#pone.0188016.t004){ref-type="table"} and [Fig 3](#pone.0188016.g003){ref-type="fig"}, the rankings of the association estimators identified by the average performance score (Avg) are varying according to the constructed module sizes and the cancer type. In the pathway-level analysis, best performing methods based on the cancer type are as follows: Shrink for BRCA, SG for GBM, Shrink for KIRC, BS for LUSC, and MM for SKCM. In addition, although the most successful predictor varies for each data set, the MI based predictors outperformed other methods in BRCA, GBM, KIRC, LUSC datasets, however only in SKCM data set, MM estimator and Kendall correlation method were found to be successful with very close average precision scores according to the pathway level analysis.

According to the average precision scores for BRCA dataset that are given in [Table 4](#pone.0188016.t004){ref-type="table"}, the ranking of the estimators is as follows: Shrink, Empirical, SG, Adjacency, BS, Pearson, Spearman, MM, Kendall and KDE. Here, Shrink method is the most accurate method in terms of identifying the disease-associated sub networks with a precision score of 0.85. Empirical, SG, Adjacency, BS, Pearson, Spearman methods follow this one with lower scores of 0.67, 0.63, 0.61, 0.59, 0.59, 0.58, respectively. Additionally, MM and Kendall methods gave comparatively lower scores of 0.52, 0.51, while KDE method gets the lowest score of 0.42.

Based on the average precision scores for GBM dataset ([Table 4](#pone.0188016.t004){ref-type="table"}), the ranking of the success rate of the estimators is as follows: SG, MM, Kendall, KDE, Shrink, BS, Empirical, Adjacency, Pearson and Spearman. Here, SG method is the most accurate one in terms of identifying disease-relevant sub networks with a precision score of 0.84. MM, Kendall, KDE, Shrink, BS methods follow this one with lower scores of 0.72, 0.67, 0.64, 0.63, 0.62, respectively. Additionally, Empirical, Adjacency and Pearson methods concluded with comparatively lower scores of 0.59, 0.58, 0.54, while Spearman method gets the lowest score of 0.46.

According to the average precision scores for KIRC dataset that are given in [Table 4](#pone.0188016.t004){ref-type="table"}, the ranking of the estimators is as follows: Shrink, MM, Adjacency, BS, Spearman, SG, Kendall, Pearson, Empirical and KDE. Here, Shrink method is identified as the most accurate one in terms of identifying disease associated sub networks with a precision score of 0.59. MM, Adjacency, BS, Spearman, SG, Kendall, Pearson methods follow this one with lower scores of 0.47, 0.46, 0.46, 0.43, 0.43, 0.43, 0.43, respectively. Additionally, Empirical method gets comparatively a lower score of 0.39, while KDE method has the lowest score of 0.34.

Based on the average precision scores for LUSC dataset that can be seen in [Table 4](#pone.0188016.t004){ref-type="table"}, the ranking of the estimators is as follows: BS, Shrink, Empirical, Adjacency, MM, SG, KDE, Pearson, Kendall and Spearman. BS and Shrink methods could identify the most disease-relevant sub networks with slightly different precision values of 0.76 and 0.75, respectively. Empirical, Adjacency, MM, SG, KDE methods followed them with lower precision scores of 0.68, 0.67, 0.67, 0.64, 0.63, respectively. Additionally, Pearson and Kendall methods obtained comparatively lower scores of 0.59, 0.51, while Spearman method gave the lowest score of 0.46.

According to the average precision scores for SKCM dataset as given in [Table 4](#pone.0188016.t004){ref-type="table"}, the accuracy ranking of the estimators is as follows: MM, Kendall, Shrink, Pearson, Spearman, Adjacency, BS, Empirical, KDE and SG. MM and Kendall methods could identify the most disease-relevant sub networks and genes with slightly different values of 0.758 and 0.757, respectively. Shrink, Pearson, Spearman, Adjacency, BS, Empirical, KDE and SG methods follow them with lower scores of 0.73, 0.71, 0.71, 0.68, 0.68, 0.68, 0.68 and 0.67, respectively.

We designed a 2-level evaluation process, i.e. pathway-level and gene-level, with stringent cut-offs to have a complementary system as explained in the methods section. In pathway-level evaluation we searched the disease-associated modules. Then, in gene-level evaluation we focused on the disease-associated modules and looked for the overlapping ratios between the member genes of these disease-associated modules and the previously reported disease, i.e. given cancer type, genes.

As given in [Table 5](#pone.0188016.t005){ref-type="table"} and [Fig 4](#pone.0188016.g004){ref-type="fig"}, the best performing association estimators according to the average precision values in the gene-level analysis are as follows: Shrink for BRCA, SG for GBM, Shrink for KIRC, BS for LUSC, and MM for SKCM. In addition, as in the pathway-level analysis, although the most successful predictor changes for each data set, the MI-based predictors were found to be more successful in BRCA, GBM, KIRC, LUSC dataset. Only in SKCM data set, MM estimator and Kendall correlation method were found to be successful with very close precision values according to both pathway-level and gene-level analyses for P-value \< 0.05.

According to the average precision scores for BRCA dataset, which are given in [Table 5](#pone.0188016.t005){ref-type="table"}, the estimators are listed as follows: Shrink, Empirical, SG, Adjacency, Pearson, MM, Kendall, BS, Spearman, and KDE. Shrink method is the most accurate one in terms of identifying disease-associated genes with a precision score of 0.85. Empirical, SG, Adjacency, Pearson methods follow this one with lower scores of 0.67, 0.63, 0.61, 0.59, respectively. Additionally, MM, Kendall, BS methods obtain comparatively lower scores of 0.52, 0.51, 051, while Spearman and KDE methods get the lowest scores of 0.45, 0.42, respectively.

Based on the average precision scores for GBM dataset that are given in [Table 5](#pone.0188016.t005){ref-type="table"}, the estimators are listed as follows: SG, MM, Kendall, Shrink, BS, KDE, Empirical, Adjacency, Pearson and Spearman. SG is the most accurate method in terms of identifying disease-associated genes with a precision score of 0.80. MM, Kendall, Shrink, BS, KDE methods follow this one with lower scores of 0.72, 0.67, 0.63, 0.62, and 0.60, respectively. Additionally, Empirical, Adjacency and Pearson methods obtain comparatively lower scores of 0.59, 0.58, 0.54, while Spearman method gets the lowest score of 0.46.

According to the average precision scores for KIRC dataset ([Table 5](#pone.0188016.t005){ref-type="table"}), the estimators are listed as follows: Shrink, BS, MM, Pearson, Adjacency, Empirical, Kendall, KDE, Spearman and SG. Shrink is the most accurate method in terms of identifying disease-associated genes with a precision score of 0.51. BS and MM methods follow this one with lower scores of 0.46, 0.43, respectively. Additionally, Pearson, Adjacency, Empirical, Kendall, KDE methods obtain comparatively lower scores of 0.38, 0.37, 0.35, 0.34, 0.34, while Spearman and SG methods have the lowest scores of 0.31 and 0.30.

Based on the average precision scores for LUSC dataset ([Table 5](#pone.0188016.t005){ref-type="table"}), the estimators are listed as follows: BS, Adjacency, Shrink, Empirical, SG, Pearson, MM, KDE, Kendall and Spearman. BS is the most accurate method in terms of identifying disease-associated genes with a precision score of 0.66. Adjacency, Shrink, Empirical, SG methods follow this one with lower scores of 0.63, 0.62, 0.59, 0.59, respectively. Additionally, Pearson, MM, KDE, Kendall methods obtain comparatively lower scores of 0.55, 0.54, 0.46, 0.43, while Spearman method gets the lowest score of 0.38.

According to the average precision scores for SKCM dataset ([Table 5](#pone.0188016.t005){ref-type="table"}), the estimators are listed from high to low scores as follows: MM, Kendall, Shrink, Pearson, Adjacency, BS, Empirical, KDE, SG, and Spearman. MM and Kendall are the most accurate methods in terms of identifying disease-associated genes with precision scores of 0.758 and 0.757, respectively. Shrink, Pearson, Adjacency, BS, Empirical, KDE, and SG methods follow them with lower scores of 0.73, 0.71, 0.68, 0.68, 0.68, 0.68, and 0.67 respectively. Additionally, Spearman method has the lowest score of 0.62.

Finally, the sub networks of the module hub genes identified by the association estimators, which provide the highest precision scores based on a statistical test (with a P-value \< 0.05), are generated by Cytoscape \[[@pone.0188016.ref045]\] and shown in Figs [5](#pone.0188016.g005){ref-type="fig"}--[9](#pone.0188016.g009){ref-type="fig"} for all cancer types for the consideration of the other researchers studying in this field. The genes registered in DisGeNET and experimentally confirmed for the diseases, are shown in Figs [5](#pone.0188016.g005){ref-type="fig"}--[9](#pone.0188016.g009){ref-type="fig"} with colored and larger nodes. Among those, genes that are not colored but have a red frame have a PMID value of one. There is no entry in DisGeNET for the grey colored nodes. Also, the most associated top three biological pathways, to which each module is related, are given above or below the relevant module to annotate each module.

Conclusion and discussion {#sec008}
=========================

Performances of nine association estimators used in the network inference algorithms were examined on the proteomic data of five different cancer types in both pathway and gene-levels. To make this assessment, selected association estimators were used instead of the adjacency matrix construction procedure in the WGCNA, which is based on either Pearson or Spearman correlation and has been used in many different studies in the literature. In conclusion, from Tables [4](#pone.0188016.t004){ref-type="table"} and [5](#pone.0188016.t005){ref-type="table"} and Figs [3](#pone.0188016.g003){ref-type="fig"} and [4](#pone.0188016.g004){ref-type="fig"}, it can be clearly observed that in terms of the precision scores, the MI based methods provide better results than the correlation-based methods and the adjacency function which is provided as a default choice in WGCNA. In parallel with the studies in the literature \[[@pone.0188016.ref046]\], our findings confirmed that the correlation-based methods are not sufficient to estimate the non-linear relationships between the cell molecules such as cancer-related complex molecular interactions.

It was observed that *PDPK1 (PDK1)*, *MSH6*, *BID*, *PECAM1 (CD31)*, *SMAD4*, *GATA3* and *NF2* hub genes (proteins) may have important effects on the breast cancer as a result of the WGCNA analysis with Shrink association estimator. DisGeNET has shown that, among these genes, *MSH6* and *GATA3* were associated with BRCA in only one study, while *RAD50*, *TSC1*, *CHEK2*, *ATM*, *STK11*, *PTEN*, *RAD51*, *BRCA2*, *TPD3*, *CHEK1*, *CCND1*, *ERBB2*, *EGFR*, and *ESR1* were validated in multiple studies. Besides, *PDK1* \[[@pone.0188016.ref047],[@pone.0188016.ref048]\] and *SMAD4* \[[@pone.0188016.ref049]\] genes (proteins) were also shown to be associated with the BRCA in multiple studies, though they were not reported in the DisGeNET.

It was found that *DIRAS3*, *RAD50*, *MAPK1 (ERK2)*, *RBM15*, *IGF1R (IGF1R_pY1135Y1136)*, *MS4A1 (CD20)*, and *COG3* hub genes (proteins) may have important effects on GBM as a result of the WGCNA analysis with SG association estimator. DisGeNET has shown that, among these genes, *IGF1R* was associated with GBM in only one study, while *CHEK2*, *KDR*, *NOTCH1*, *MSH2*, *BCL2*, *ERBB2*, *PDCD4*, *FOXM1*, *PTEN*, *CASP3*, *EGFR*, *TP53BP1*, *IGFBP2*, *RAF1*, *SMAD3*, *SETD2*, *MTOR*, *TP53*, *BRAF*, *MSH6*, *TSC1*, *STAT3*, *MET*, and *PIK3CA* were validated in multiple studies. Besides, in recent studies, *RAD50* \[[@pone.0188016.ref050]\] gene (protein) was also shown to be associated with the GBM, though it was not reported in the DisGeNET.

It was observed that ADAR (ADAR1), CCNE2 (CYCLINE2), BID, CDKN1B (P27_Pt198), and PRKCA (PKCALPHA) hub genes (proteins) may have significant effects on KIRC as a result of the WGCNA analysis with Shrink association estimator. Thus far, from the DisGeNET, we could not find any evidences that these genes are associated with KIRC. DisGeNET has shown that, ATM, MTOR, TP53, TSC2, ESR1, BCL2, KDR, STAT3, TSC1, and PRKCB were validated in multiple studies.

It was found that *EIF4G1 (EIF4G)*, *FOXM1*, *COPS5 (JAB1)*, *CDKN1A (P21)*, *MRE11A (MRE11)*, and *PRKCB (PKCPANBETAII_pS660)* hub genes (proteins) may have significant effects on LUSC as a result of the WGCNA analysis with BS association estimator. DisGeNET has shown that, among these genes, *EIF4G1 (EIF4G)* gene (protein) was associated with LUSC in two studies, while *CDH1*, *CDKN2A*, *PIK3CA*, *EGFR*, *TP53*, and *STAT3* were confirmed as disease genes in multiple studies. Besides, in recent studies, *FOXM1* \[[@pone.0188016.ref051],[@pone.0188016.ref052]\] and *CDKN1A (P21)* \[[@pone.0188016.ref053]\] genes (proteins) were also shown to be associated with the LUSC in multiple studies though they were not reported in the DisGeNET.

It was observed that *MRE11A (MRE11)*, *ETS1*, *BAX*, *COPS5 (JAB1)*, *TSC2 (TUBERIN_pT1462)*, and *SYK* hub genes (proteins) may have significant effects on SKCM as a result of the WGCNA analysis with MM association estimator. DisGeNET has shown that, *EGFR*, *RAF1*, *PTEN*, *ERCC5*, *CCND1*, *BRCA2*, *PCNA*, *ERBB2*, *TSC1*, *CASP8*, *TP53*, *PIK3CA*, *NRAS*, *BCL2*, *KIT*, *FASN*, *CTNNB1*, *CDKN2A*, *BRAF*, *YAP1*, and *MSH2* were highlighted as disease genes in multiple studies. Besides, in recent studies, *ETS1* \[[@pone.0188016.ref054]\] gene (protein) was also shown to be associated with the SKCM, though it was not reported in the DisGeNET.

As a conclusion, despite not being included in DisGeNET, the genes that are found to be related with the disease via recent studies in the literature (*PDK1*, *SMAD4*, *RAD50*, *FOXM1*, *CDKN1A*, *ETS1* \[[@pone.0188016.ref047]--[@pone.0188016.ref054]\]) were detected with our proposed framework. Studies verify that these genes (proteins) are associated with cancer-related processes. Du et al. identified the *PDK1* as a potential therapeutic target for BRCA \[[@pone.0188016.ref047]\]. Dupuy et al. also determined the *PDK1* as a key regulator of metabolism and metastatic potential in BRCA \[[@pone.0188016.ref048]\]. Liu at el. indicated that the assessment of *SMAD4* protein level may provide additional prognostic information about BRCA \[[@pone.0188016.ref049]\]. Mishima et al. found out that *MRE11-RAD50-NBS1* complex inhibitor can effectively increase radiosensitivity in GBM \[[@pone.0188016.ref050]\]. Sun et al. showed the prognostic significance of *FOXM1* expression in LUSC \[[@pone.0188016.ref051]\]. Zhang et al. remarked the *FOXM1* as a novel biomarker of LUSC \[[@pone.0188016.ref052]\]. Fukazawa et al. found out that the tumorigenic effect of *SOX2* on LUSC is mediated in part by suppression of *CDKN1A* \[[@pone.0188016.ref053]\]. Keehn et al. stated that *ETS1* may be important in the pathogenesis of invasive SKCM \[[@pone.0188016.ref054]\]. Thus, since our proposed method could capture this long list of previously studied genes, it is suggested that it might capture a more comprehensive list of the disease associated gene-gene interactions that were missed in previous studies.

The most significant contribution of our study is the use of different association estimators in biological network inferring methodologies, which can make a significant improvement in identifying the disease-associated co-expression modules when they are integrated with the WGCNA method. In addition, similar performance scores of each estimator in pathway-level and gene-level analysis also indicate the consistency of our study.
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